Enzolytics, Inc. (OTCMKTS:ENZC) Sees Large Drop in Short Interest

Enzolytics, Inc. (OTCMKTS:ENZC) was the recipient of a significant decline in short interest in the month of March. As of March 13th, there was short interest totaling 209 shares, a decline of 88.8% from the February 26th total of 1,874 shares. Based on an average trading volume of 21,871,786 shares, the short-interest ratio is presently 0.0 days.

Enzolytics Stock Performance

Enzolytics stock remained flat at $0.00 during midday trading on Thursday. 19,570 shares of the company’s stock traded hands, compared to its average volume of 8,823,497. Enzolytics has a 12-month low of $0.00 and a 12-month high of $0.00.

About Enzolytics

Enzolytics, Inc is a clinical-stage biotechnology company focused on advancing immunotherapeutic treatments for infectious diseases. Its core platform employs proprietary peptide and monoclonal antibody technologies designed to target and neutralize viral pathogens. The company’s lead candidate, Investigator Therapeutic Vaccine-1 (ITV-1), is a 72-amino-acid peptide engineered to bind multiple HIV-1 strains and support immune response in affected individuals.

In addition to its HIV program, Enzolytics has leveraged its antibody discovery engine to develop broadly neutralizing monoclonal antibodies against coronaviruses, including SARS-CoV-2.